Actively Recruiting
Comparing Liver Transplantation and Liver Surgery After Conversion Therapy for Initially Unresectable Colorectal Liver Metastases
Led by Niguarda Hospital · Updated on 2026-07-17
70
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating liver transplantation versus radical local treatment, including hepatic resection andor ablation, in patients with colorectal liver metastases CRLM that were initially unresectable but became resectable after systemic conversion therapy. This study aims to compare these two approaches to improve curative treatment strategies for this patient group. It is a single-center, randomized, open-label, proof-of-concept trial enrolling 70 patients. Liver metastases are a leading cause of death in colorectal cancer, and current surgery after chemotherapy has challenges including recurrence and liver injury. Participants receive systemic therapy first to convert unresectable liver metastases to resectable status. Then, they are randomized to either liver transplantation or radical local treatment with hepatic resection andor ablation. Patients assigned to liver transplantation continue systemic therapy until listed for transplant, with reassessments if delays or disease progression occur. Those in the surgical arm undergo resection with or without ablation, aimed at complete tumor removal. Postoperative and post-transplant care follow institutional standards. During the study, participants undergo clinical, laboratory, and imaging assessments to monitor disease status, treatment safety, and outcomes. The primary measure is 3-year overall survival. Secondary measures include disease-free survival, perioperative morbidity and mortality, treatment adherence, quality of life, and exploratory analyses such as radiomics and circulating tumor DNA. Follow-up is conducted according to study protocol and clinical practice, with an estimated total study duration of five years.
CONDITIONS
Brief Title
TRANsplantation vs reSECTion After Conversion Therapy for Initially Unresectable Colorectal Liver Metastases
Research Team
S
Stefano Di Sandro, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here